Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Prison authorities say they are investigating 'pharma bro' Shkreli

Published 03/08/2019, 09:06 PM
Updated 03/08/2019, 09:06 PM
© Reuters. Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City

By Brendan Pierson

NEW YORK (Reuters) - The U.S. Bureau of Prisons said on Friday it was investigating former drug company executive Martin Shkreli's conduct in prison after the Wall Street Journal reported he was still helping run his old company using a contraband cellphone.

"When there are allegations of misconduct, they are thoroughly investigated and appropriate action is taken if such allegations are proven true," the Bureau of Prisons said in a statement. "This allegation is currently under investigation."

The investigation was first reported by the Journal.

The bureau said that possessing a contraband cellphone was considered a severe offense and could result in discipline, including being separated from the inmate population and having visits restricted. It also said that possessing a contraband phone could lead to criminal charges.

Benjamin Brafman, a lawyer for Shkreli, declined to comment.

The Journal reported on Thursday that Shkreli, 35, still wields significant influence over the drug company he founded, Phoenixus AG, formerly called Turing Pharmaceuticals. Shkreli is about 17 months into a seven-year prison sentence for defrauding investors in a previous company.

The FBI has interviewed Shkreli's associates about his role in the company, the Journal said, citing unnamed people who had been interviewed. The FBI did not immediately respond to a request for comment.

Shkreli, born in Brooklyn to Albanian immigrant parents, became known as the "Pharma Bro" in September 2015 after founding Turing Pharmaceuticals, buying the anti-parasitic drug Daraprim and raising its price by 5,000 percent to $750 per pill. In December 2015, he was indicted on unrelated securities fraud charges.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Prosecutors said he defrauded investors in two hedge funds he ran, MSMB Capital and MSMB Healthcare, schemed to prop up the stock price of Retrophin, the drug company he founded in 2011. A jury in federal court in Brooklyn found him guilty in August 2017.

He is at Federal Correctional Institution, Fort Dix, a low-security prison in New Jersey.

Latest comments

this nutjob should be in solitary confinement for life
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.